Genomic Diagnostics Continue to Advance, Though Commercialization Poses Challenges
March 16, 2011
Genomic Diagnostics Continue to Advance, Though Commercialization Poses Challenges
At the Future of Genomics Medicine conference hosted earlier this month by the Scripps Translational Research Institute, several speakers discussed the rapid progress they have made in developing genomic tests to detect disease and guide treatment, as well as the hurdles to commercialization.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CardioDx Says $58M Financing Will Support Commercial Expansion Following Medicare Coverage Win
August 29, 2012 / Pharmacogenomics Reporter - Medicare to Cover Genomic Health's Oncotype DX Breast Cancer Test for DCIS
May 13, 2013 / GenomeWeb Daily News - CAP Accredits CardioDx's Laboratory
May 9, 2013 / GenomeWeb Daily News - CardioDx, Core Diagnostics India Reach Agreement to Offer CAD Test in India
April 25, 2013 / GenomeWeb Daily News - Prostate Cancer Risk Markers Show Promise for Test to ID Elevated Risk in Men with Benign Hyperplasia
April 3, 2013 / Pharmacogenomics Reporter